title: Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.
abstract: Novel therapeutic options for patients with recurrent primary central nervous system lymphoma (RPCNSL) are needed. Bendamustine, a bifunctional purine analog/alkylating agent, is approved for use in patients with progressive systemic indolent non-Hodgkin's B-cell lymphomas. Limited data suggests that bendamustine may partition into the brain in the setting of a disrupted blood-brain barrier. This report describes the first known experience of patients with RPCNSL treated with bendamustine. Therapy was well-tolerated and best response was noted as stable disease after eight cycles of bendamustine followed by a subsequent local systemic recurrence found at five months follow-up. CNS involvement in this patient remained stable 20 + months post-bendamustine treatment. Based on our observations, further neuropharmacokinetic and efficacy studies with bendamustine may be warranted in this patient population.
authors.affiliation: Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
authors.forename: Jaclyn J
authors.initials: JJ
authors.lastname: Renfrow
authors.forename: Alisha
authors.initials: A
authors.lastname: Detroye
authors.forename: Michael
authors.initials: M
authors.lastname: Chan
authors.forename: Stephen
authors.initials: S
authors.lastname: Tatter
authors.forename: Thomas
authors.initials: T
authors.lastname: Ellis
authors.forename: Kevin
authors.initials: K
authors.lastname: McMullen
authors.forename: Annette
authors.initials: A
authors.lastname: Johnson
authors.forename: Ryan
authors.initials: R
authors.lastname: Mott
authors.forename: Glenn J
authors.initials: GJ
authors.lastname: Lesser
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000503:physiopathology; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride